Date: 2012-06-29
Type of information: Private placement
Company: MDxHealth (Belgium)
Investors:
Amount: € 10 million
Funding type: private placement of new shares
Planned used: The net proceeds of the private placement will be used, firstly and mainly to support and scale-up a US-based sales and marketing team, subsequently to operate and scale-up the Company’s U.S.-based CLIA-registered commercial laboratory and finally, depending on the amount raised, to accelerate product development.
Others: MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, has successfully raised € 10,000,000 million in gross proceeds through a private placement of new shares with investors in various jurisdictions. Pursuant to the private placement, MDxHealth will issue 1,996,008 new ordinary shares to Biovest Comm. VA. at an offer price of € 1.503 and 4,895,105 new ordinary shares to a range of other investors at an offer price of € 1.430 (i.e. the previous closing price of the shares).
The payment and delivery of the new shares is expected to take place on July 4, 2012, at which date the new shares are also expected to be admitted to listing, subject to the approval and publication of a listing prospectus. The new shares will be fully interchangeable with the existing shares on NYSE Euronext. Immediately after the closing of the private placement, MDxHealth’s issued and outstanding shares will increase by 27% from 18,622,327 to 25,513,440 ordinary shares.
Therapeutic area: Cancer - Oncology
